What PD-1 Receptor Does Pembrolizumab Target?
Pembrolizumab (Keytruda) is a monoclonal antibody that binds to and inhibits the programmed cell death protein 1 (PD-1) receptor on T cells. PD-1 is a single immune checkpoint receptor encoded by the human PDCD1 gene. Pembrolizumab blocks PD-1's interaction with its ligands, PD-L1 (CD274) and PD-L2 (PDCD1LG2), preventing immune suppression and enabling T-cell activation against cancer cells.[1]
How Does Pembrolizumab Bind to PD-1?
Pembrolizumab attaches to the extracellular domain of human PD-1 with high affinity (KD ≈ 27 pM). This steric hindrance disrupts PD-1 signaling through its ITIM and ITSM motifs, halting downstream phosphatase recruitment like SHP-2. It does not affect PD-1 on non-human species due to epitope specificity.[1][2]
Does It Inhibit Other PD-1 Isoforms or Related Receptors?
Human PD-1 has no known functional isoforms; pembrolizumab targets the canonical full-length protein. It shows no binding to related receptors like PD-L1 or CTLA-4, distinguishing it from bispecific agents.[2]
How Does This Compare to Nivolumab or Other PD-1 Inhibitors?
| Inhibitor | PD-1 Binding Affinity (KD) | Key Difference |
|-----------|----------------------------|---------------|
| Pembrolizumab | 27 pM | IgG4 isotype; lower Fc effector function |
| Nivolumab (Opdivo) | 2.9 nM | IgG4 with S228P mutation; higher ADCC potential |
| Cemiplimab (Libtayo) | 0.42 nM | Similar IgG4 profile; approved for cutaneous SCC |
All inhibit the same human PD-1 receptor but differ in pharmacokinetics and immunogenicity.[2][3]
Clinical Implications of PD-1 Inhibition
By blocking PD-1, pembrolizumab treats cancers like melanoma, NSCLC, and MSI-high tumors where PD-L1 expression predicts response (e.g., TPS ≥50% for first-line NSCLC). Resistance can arise via PD-1 mutations or alternative checkpoints like LAG-3.[3]
[1]: FDA Label for Keytruda
[2]: DrugPatentWatch.com - Pembrolizumab Patent Details
[3]: NEJM - Pembrolizumab Mechanism Review (2015)